Now, a new blood test that detects traces of lung cancer DNA could help identify patients at risk of recurrence months before the disease becomes visible on scans. The findings may pave the way for more personalized follow-up care and treatment after surgery.

The study, published in The Journal of Molecular Diagnostics, suggests that liquid biopsies could eventually complement standard imaging and help doctors tailor follow-up care according to each patient’s risk of recurrence. However, further research is necessary to establish how best to use these tests in routine clinical practice and whether acting on their results improves long-term survival.